Hung Ben P, Hutton Daphne L, Kozielski Kristen L, Bishop Corey J, Naved Bilal, Green Jordan J, Caplan Arnold I, Gimble Jeffrey M, Dorafshar Amir H, Grayson Warren L
Department of Biomedical Engineering.
Translational Tissue Engineering Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Stem Cells. 2015 Sep;33(9):2773-84. doi: 10.1002/stem.2060. Epub 2015 Jun 26.
Tissue engineering using mesenchymal stem cells (MSCs) holds great promise for regenerating critically sized bone defects. While the bone marrow-derived MSC is the most widely studied stromal/stem cell type for this application, its rarity within bone marrow and painful isolation procedure have motivated investigation of alternative cell sources. Adipose-derived stromal/stem cells (ASCs) are more abundant and more easily procured; furthermore, they also possess robust osteogenic potency. While these two cell types are widely considered very similar, there is a growing appreciation of possible innate differences in their biology and response to growth factors. In particular, reports indicate that their osteogenic response to platelet-derived growth factor BB (PDGF-BB) is markedly different: MSCs responded negatively or not at all to PDGF-BB while ASCs exhibited enhanced mineralization in response to physiological concentrations of PDGF-BB. In this study, we directly tested whether a fundamental difference existed between the osteogenic responses of MSCs and ASCs to PDGF-BB. MSCs and ASCs cultured under identical osteogenic conditions responded disparately to 20 ng/ml of PDGF-BB: MSCs exhibited no difference in mineralization while ASCs produced more calcium per cell. siRNA-mediated knockdown of PDGFRβ within ASCs abolished their ability to respond to PDGF-BB. Gene expression was also different; MSCs generally downregulated and ASCs generally upregulated osteogenic genes in response to PDGF-BB. ASCs transduced to produce PDGF-BB resulted in more regenerated bone within a critically sized murine calvarial defect compared to control ASCs, indicating PDGF-BB used specifically in conjunction with ASCs might enhance tissue engineering approaches for bone regeneration.
使用间充质干细胞(MSCs)的组织工程在修复临界尺寸的骨缺损方面具有巨大潜力。虽然骨髓来源的MSCs是该应用中研究最广泛的基质/干细胞类型,但其在骨髓中稀少且获取过程痛苦,这促使人们研究替代细胞来源。脂肪来源的基质/干细胞(ASCs)更为丰富且更容易获取;此外,它们还具有强大的成骨能力。虽然这两种细胞类型被广泛认为非常相似,但人们越来越认识到它们在生物学特性和对生长因子反应方面可能存在内在差异。特别是,有报道表明它们对血小板衍生生长因子BB(PDGF - BB)的成骨反应明显不同:MSCs对PDGF - BB反应消极或根本无反应,而ASCs在生理浓度的PDGF - BB作用下表现出矿化增强。在本研究中,我们直接测试了MSCs和ASCs对PDGF - BB的成骨反应之间是否存在根本差异。在相同成骨条件下培养的MSCs和ASCs对20 ng/ml的PDGF - BB反应不同:MSCs的矿化没有差异,而ASCs每个细胞产生更多的钙。ASCs内siRNA介导的PDGFRβ敲低消除了它们对PDGF - BB的反应能力。基因表达也不同;MSCs通常下调,而ASCs通常上调对PDGF - BB反应的成骨基因。与对照ASCs相比,转导产生PDGF - BB的ASCs在临界尺寸的小鼠颅骨缺损中导致更多的再生骨,这表明与ASCs特异性结合使用的PDGF - BB可能会增强骨再生的组织工程方法。